Earnings on the Doorstep For Allergan plc

Allergan plc (AGN) has been given an average price target of $270.44 from analysts, according to data collected by Finviz.

COPYRIGHT VIOLATION WARNING: "Allergan plc (AGN) Shares Sold by Duff & Phelps Investment Management Co." was originally posted by BBNS and is the property of of BBNS. The company reported $3.90 earnings per share for the quarter, beating analysts' consensus estimates of $3.76 by $0.14.

Blackrock Japan Company Ltd decreased B/E Aerospace Inc (NASDAQ:BEAV) stake by 54,031 shares to 121,874 valued at $7.34 million in 2016Q4.

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. High Point Bank & Trust Co. increased its stake in Allergan plc by 3.6% in the third quarter. Hedge funds and other institutional investors own 86.40% of the company's stock. Finally, Citizens Financial Group Inc RI increased its stake in Allergan plc by 133.9% in the third quarter. TX now owns 1,361 shares of the company's stock worth $313,000 after buying an additional 60 shares during the period. LLC purchased a new stake in Allergan plc during the fourth quarter worth approximately $136,000.

As the earnings date approaches, we can see that insider ownership is now 0.20% shares, and institutional ownership is at 94.30% for Allergan plc (NYSE:AGN) stock.

During last 5 trades the stock sticks nearly 0.44%.

After a recent look, shares have been seen 5.98% from the 200-day moving average, and 0.78% from the 50-day moving average. The current share price indicates that stock is -7.13% away from its one year high and is moving 31.51% ahead of its 52-week low.

Allergan plc (NYSE:AGN)'s earnings is on the doorstep as the firm is set to report on 5/9/2017 8:30:00 AM.

Analysts on a consensus basis are expecting that the stock will reach $277.1 within the year.

The company raised its net revenue forecast to $15.8 billion-$16 billion, from $15.5 billion-$15.8 billion. During the same period in the prior year, the business posted $3.41 earnings per share.

Heading into the earnings release, covering sell-side analysts have a consensus target price of $273.69 on Allergan plc shares.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Thursday, May 18th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.14%. If you are reading this article on another site, it was illegally stolen and republished in violation of United States and worldwide copyright laws.

A number of equities research analysts have recently issued reports on AGN shares. Vetr upgraded shares of Allergan plc from a "hold" rating to a "buy" rating and set a $224.07 price target on the stock in a research note on Tuesday, January 17th. Piper Jaffray Companies set a $205.00 target price on Allergan plc and gave the stock a "hold" rating in a research report on Wednesday, February 22nd. Credit Suisse maintained it with "Outperform" rating and $274 target in Friday, December 9 report. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The relative volume (ratio between current volume and 3-month average) is presently sitting at 0.80.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock. The shares were sold at an average price of $246.68, for a total transaction of $17,267,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company's stock.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced that it will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16, 2017, at 10:00 a.m.